Drug intelligence / Profile preview

SWIM-816

Development stage: Phase 3
Lead developer: Stemirna Therapeutics
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

SWIM-816 is a prophylactic mRNA vaccine developed by Stemirna Therapeutics for the prevention of COVID-19. It functions as an immunostimulant, designed to elicit an immune response against SARS-CoV-2 infection. The drug is currently in Phase 2/3 clinical trials, where it is being evaluated for its immunogenicity, safety, and efficacy as a heterologous booster dose in adults previously vaccinated with other COVID-19 vaccines. Its primary therapeutic area is infectious diseases, specifically respiratory diseases such as COVID-19.

Other names: SWIM816SWIM-816SWIM 816

Beyond the preview

Go deeper on SWIM-816.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SWIM-816.

Explore the full profile